Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

a first-line randomized phase II/III study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone as part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate similar objective response rates to the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. A total of 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines. The main adverse events associated with pixantrone in clinical trials to date include myelosuppression and alopecia.

About NHL

According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology pro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 ... announced it has signed a definitive agreement ... provider of non-invasive ventilation and sleep-disordered breathing ... strong clinical, innovation and market reputation in China, combined with ResMed,s global leadership ... of people in China ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... AZ (PRWEB) , ... August 03, 2015 , ... Dignity ... Dignity Health Arizona General Hospital Emergency Room – Gilbert, opening in August. The ... earlier this year in the West Valley. , “Dr. Baldwin is an excellent ...
(Date:8/3/2015)... ... 2015 , ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) ... medical practice in the Mid-Atlantic region – and the second largest in the United ... doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in Laurel, ...
(Date:8/3/2015)... ... ... Recent reports by the American Medical Association show that over 80% of Americans ... low back and sciatic pain can happen as a result of vertebral disc herniations ... medication or spinal surgery. Dynamic Health Care in Louisville, KY , has implemented ...
(Date:8/2/2015)... Birmingham, Lake Orion, Clarkston, Metamora Michigan (PRWEB) , ... ... ... Pelvic Organ Prolapse (POP) results when the supportive muscles and ... weakened or damaged. Causes of this weakness and damage include straining, heavy ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2
... Nov. 6 The following was released today,by ... recent report from the U.S. Department of Veterans ... substantiated waste,mismanagement and inaction to disclosures of fraud, ... Texas Veterans Health,Care System (CTVHCS)., Inaction to ...
... ) today reported results for the third quarter ended September,30, ... or $0.11 per,share, for the third quarter 2008 compared to ... the third quarter 2007. Cash and cash equivalents,totaled $6.1 million ... for the third quarter 2008 is due primarily to,a 26% ...
... vitality unclear, scientists say , , THURSDAY, Nov. 6 (HealthDay ... amounts of muscle-linked growth hormone in seniors to youthful ... therapy also gained muscle mass over the two-year trial, ... led to significant improvements in their strength or function. ...
... Conference Call Scheduled for Today - Thursday, November 6, 2008 at ... ... Calif., Nov. 6 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported ... 30, 2008, and provided an,update on its product development candidates. The ...
... MASI ), the inventor of Pulse CO-Oximetry(TM) and ... its,management is scheduled to present at the Lazard Capital ... York in New York, NY on,Wednesday, November 19, 2008, ... will be available on the Masimo website at, http://www.masimo.com ...
... RANCHO CORDOVA, Calif., Nov. 6 ThermoGenesis,Corp. (Nasdaq: ... that process and store adult stem cells, today reported ... for the quarter ended September 30, 2008, were $4.5 ... in the first quarter a,year ago. Disposable revenues were ...
Cached Medicine News:Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 2Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 3Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 5Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 6Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 7Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 8Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 9Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 10Health News:Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference 2Health News:ThermoGenesis Reports First Quarter 2009 Results 2Health News:ThermoGenesis Reports First Quarter 2009 Results 3Health News:ThermoGenesis Reports First Quarter 2009 Results 4Health News:ThermoGenesis Reports First Quarter 2009 Results 5Health News:ThermoGenesis Reports First Quarter 2009 Results 6Health News:ThermoGenesis Reports First Quarter 2009 Results 7Health News:ThermoGenesis Reports First Quarter 2009 Results 8
The ENDO CLOSE™ trocar site closure device has application in laparoscopic procedures for approximation of tissues and percutaneous suturing for closing incision sites....
... of a 42" long suture inserted into a ... one end and scored on the other. The ... to a ST-3 needle. The opposite end of ... of the plastic tube. The scored end acts ...
... long ligature inserted into a plastic tube. The plastic ... the other. The suture protrudes from the narrow end ... knot which becomes secure after the device is activated. ... the scored end of the plastic tube. The scored ...
... consists of 18'' long ligature inserted into a plastic ... and scored on the other. The suture protrudes from ... loop with a knot which becomes secure after the ... is fastened to the scored end of the plastic ...
Medicine Products: